Tagged with Exclusive

Switzerland Dr Srishti Gupta brings a distinctive combination of medical training, health policy insight, and strategic consulting to her role as CEO of Idorsia Pharmaceuticals. A Harvard-trained biochemist and physician, she spent 18 years at McKinsey & Company advising life sciences and global health clients. Committed to reducing healthcare inequities and…

France With demand for plasma-derived therapies rising steadily and Europe rethinking its biomanufacturing sovereignty, France’s LFB is quietly positioning itself for a leap onto the global stage. Backed by a EUR 750 million investment in a new industrial site and a unique public health mandate, the state-owned player is not just…

Brazil Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect of the organisation’s strategic transformation. His tenure spans critical periods of regulatory modernisation, digital transformation, and international collaboration, positioning him…

Switzerland Over the past decade, Dr Lutz Hegemann has helped transform Novartis’ Global Health unit into a strategic pillar that bridges innovation with real-world access. Rather than focusing on visibility, the mandate centres on sustainable impact; embedding access into R&D, rethinking the value of established medicines, and advocating for systemic change…

Denmark Neuroscience is once again at the forefront of medical innovation, and Lundbeck is seizing the moment to redefine its future. In this wide-ranging conversation, President & CEO Charl van Zyl outlines how the company is evolving from a heritage-rich organisation into a focused, performance-driven innovator with a maturing pipeline and…

Global As neuroscience reclaims a place at the top table of pharmaceutical innovation, Bristol Myers Squibb (BMS) is quietly reshaping its presence in the field. Spearheaded by its Neuroscience Thematic Research Center, the company is pursuing a dual mandate: to slow the progression of diseases like Alzheimer’s while also addressing their…

Denmark As Denmark sets its sights on becoming a global leader in life sciences by 2030, Morten Bødskov, Minister for Industry, Business, and Financial Affairs, outlines the strategic pillars of the country’s Life Science Strategy Toward 2030. With an unwavering commitment to strengthening Denmark’s competitive edge in the face of fierce…

Switzerland The Federal Office of Public Health (FOPH) is the body responsible for safeguarding public health in Switzerland, developing national health policies, and overseeing the Swiss healthcare system. In an exclusive conversation, FOPH Director Anne Lévy discusses the key challenges facing the Swiss healthcare system today and highlights potential solutions as…

Hong Kong Prof. Lo Chung-mau, Hong Kong’s Secretary for Health, delves into some of the key strategic initiatives for advancing Hong Kong’s healthcare and biomedical innovation. Key topics include the integration of the Greater Bay Area (GBA) for enhanced clinical trials, addressing the increasing needs of Hong Kong healthcare system, and leveraging…

Morocco With a generational universal healthcare reform underway in Morocco, the country’s Minister of Health and Social Protection Khalid Aït Taleb outlines why the ongoing updates to his country’s healthcare system far outweigh what has gone before in terms of scale and scope. Minister Aït Taleb also touches on digitalisation and…

Europe As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for the coming year, including the lessons to be taken from the pandemic response, why antimicrobial resistance must not be neglected,…

Europe In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the Agency’s approach to antimicrobial resistance, and highlights how it hopes to contribute to a stronger European clinical trials ecosystem.  …